Published: November 5, 2012

InSphero ranked #2 Startup of the Year in Switzerland

InSphero ranked #2 Startup of the Year in Switzerland

Zurich, Switzerland, November 5, 2012 – InSphero AG, experts in three-dimensional microtissue technology, is proud to announce that the company has been ranked number 2 on the TOP 100 Swiss Startups 2012 list and recognized for its global success and customer base of top pharmaceutical companies.

Around 100 experts from the Swiss business startup scene have ranked InSphero as the number 2 startup (across all categories) in Switzerland and, again, as in 2011, the number 1 startup in the biotech space. The jury recognized the global success of InSphero’s 3D microtissue technology for more predictive compound testing and the fact that InSphero currently counts 7 of the top 10 global pharmaceutical and cosmetics companies as customers.

Dr. Jan Lichtenberg, Chief Executive Officer and Co-founder of InSphero, says: “At InSphero, we are very proud of the accomplishment and appreciate the recognition accorded to the company and its dedicated employees. This is a great success for us, given the strengths of other startup companies in Switzerland. At the same time, this high ranking is a clear indication that business veterans, investors, and startup experts recognize the global awareness that InSphero has generated for 3D cell culture and its sustainably growing business.”

Other News

News

InSphero Appoints Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer

InSphero has appointed Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer, expanding his leadership role as the company continues to grow and scale. With nearly a decade at InSphero and deep expertise across microfluidics, BioMEMS, 3D in vitro models, and organ-on-chip technologies, Olivier will bring technology and operations into closer alignment. In his new role, he will help advance operational efficiency, digitalization, automation, and technology development across the organization.

Read More »
News

InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment 

InSphero has launched the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput solution designed to identify gastrointestinal safety liabilities earlier in drug discovery. Combining patient-derived human intestinal organoids, scalable Gri3D® technology, and automated phenotypic imaging, the platform delivers quantitative, decision-ready insights while enabling more consistent and streamlined GI safety assessment.

Read More »

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource